Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 3/20 | 0.45 |
| ▸ | PPARA | Q07869 | 3/20 | 0.45 |
| ▸ | PTPRB | P23467 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 6/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 6/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5123818 | 0.84 | KDM4E (0.50) | PPARDPPARAPTPRBPPARGP2RX7 | |
| SCHEMBL4779923 | 0.84 | P2RX7 (0.44) | PPARDPPARANR3C2PTPN7DUSP3 | |
| SCHEMBL4436198 | 0.83 | EPHX1 (0.46) | PPARDPPARANR3C2PPARGPTPN7 | |
| SCHEMBL16798238 | 0.83 | PTPRB (0.50) | PPARDPPARAPTPRBPPARG | |
| SCHEMBL27793346 | 0.80 | PTPN7 (0.41) | PPARDPPARANR3C2PTPN7DUSP3 | |
| SCHEMBL14032994 | 0.79 | PTPRB (0.47) | PPARDPPARAPTPRBPPARG | |
| SCHEMBL15262395 | 0.79 | EPHX2 (0.42) | PPARDPPARANR3C2PPARGPTPN7 | |
| SCHEMBL2426042 | 0.78 | PPARG (0.41) | PPARDPPARAPPARGPTPN7DUSP3 | |
| SCHEMBL29649429 | 0.78 | TAS1R3 (0.44) | PPARDPPARAPTPN7DUSP3 | |
| SCHEMBL20714549 | 0.78 | TAS1R3 (0.44) | PPARDPPARAPTPN7DUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101801972-A | Pyrazolo [1,5-A]pyrimidines as inhibitors of stearoyl-coA desaturase | INOVACIA AB | 2010-08-11 | — | — | CN | disclosed |
| US-20080255153-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255153-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255153-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-10-16 | — | — | US | disclosed |
| WO-2008116898-A1 | PYRAZOLO [1,5-A]PYRIMIDINES AS INHIBITORS OF STEAROYL-COA DESATURASE | BIOVITRUM AB (PUBL) (SE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255153-A1 | New compounds | SCD, SCD5, FADS2 | PPARD 220/4885PPARA 278/4885PTPRB 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.